🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 04/09/2014 | 92,99 | 93,41 | 90,99 | 91,55 | -1,37% | 2,60% | 864.900 |
| 03/09/2014 | 93,20 | 93,99 | 92,26 | 92,82 | -0,15% | 1,86% | 660.100 |
| 02/09/2014 | 94,29 | 94,30 | 91,69 | 92,96 | -0,65% | 2,77% | 1.289.800 |
| 29/08/2014 | 93,08 | 94,00 | 92,40 | 93,57 | +0,83% | 1,72% | 723.200 |
| 28/08/2014 | 92,55 | 94,08 | 92,34 | 92,80 | -0,25% | 1,88% | 557.400 |
| 27/08/2014 | 94,03 | 94,30 | 92,71 | 93,03 | -0,65% | 1,69% | 837.000 |
| 26/08/2014 | 90,89 | 94,50 | 90,89 | 93,64 | +2,05% | 3,97% | 1.893.600 |
| 25/08/2014 | 91,13 | 92,55 | 90,51 | 91,76 | +1,71% | 2,24% | 971.900 |
| 22/08/2014 | 89,50 | 90,63 | 88,67 | 90,22 | +1,38% | 2,19% | 862.400 |
| 21/08/2014 | 91,32 | 91,88 | 88,38 | 88,99 | -2,53% | 3,83% | 1.007.400 |
| 20/08/2014 | 91,46 | 92,73 | 90,57 | 91,30 | -0,67% | 2,36% | 1.071.400 |
| 19/08/2014 | 90,85 | 92,25 | 90,68 | 91,92 | +0,68% | 1,73% | 894.200 |
| 18/08/2014 | 91,11 | 92,40 | 90,61 | 91,30 | +0,46% | 1,96% | 1.147.800 |
| 15/08/2014 | 90,87 | 91,85 | 89,55 | 90,88 | +0,56% | 2,53% | 1.053.300 |
| 14/08/2014 | 88,46 | 90,43 | 88,11 | 90,37 | +1,83% | 2,62% | 1.156.400 |
| 13/08/2014 | 84,41 | 89,13 | 84,41 | 88,75 | +3,91% | 5,59% | 1.386.800 |
| 12/08/2014 | 86,02 | 86,59 | 84,94 | 85,41 | -0,92% | 1,92% | 710.200 |
| 11/08/2014 | 85,97 | 86,71 | 84,47 | 86,20 | -0,25% | 2,61% | 959.500 |
| 08/08/2014 | 85,20 | 86,99 | 85,18 | 86,42 | +1,98% | 2,12% | 986.400 |
| 07/08/2014 | 86,94 | 87,45 | 84,60 | 84,74 | -2,38% | 3,28% | 1.388.800 |
| 06/08/2014 | 86,31 | 87,55 | 85,71 | 86,81 | -0,22% | 2,13% | 1.195.400 |
| 05/08/2014 | 86,18 | 88,06 | 85,70 | 87,00 | +0,36% | 2,74% | 1.492.700 |
| 04/08/2014 | 88,37 | 89,99 | 86,10 | 86,69 | -0,96% | 4,40% | 1.964.600 |
| 01/08/2014 | 89,60 | 90,37 | 86,56 | 87,53 | -1,55% | 4,25% | 2.479.400 |
| 31/07/2014 | 90,64 | 91,85 | 88,11 | 88,91 | -3,37% | 4,13% | 2.470.100 |
| 30/07/2014 | 93,49 | 95,24 | 91,31 | 92,01 | -3,71% | 4,20% | 2.295.400 |
| 29/07/2014 | 95,40 | 96,63 | 95,25 | 95,56 | +0,00% | 1,45% | 1.449.700 |
| 28/07/2014 | 95,48 | 96,29 | 95,24 | 95,56 | -0,20% | 1,10% | 1.178.300 |
| 25/07/2014 | 96,01 | 96,81 | 94,67 | 95,75 | -0,02% | 2,23% | 1.259.000 |
| 24/07/2014 | 97,87 | 98,45 | 95,68 | 95,77 | -2,41% | 2,83% | 1.959.100 |